Millipore Sigma Vibrant Logo

531167 GSK-3 Inhibitor XXIX, CHIR98014 - CAS 252935-94-7 - Calbiochem

Aperçu

Replacement Information

Tableau de caractéristiques principal

CAS #Empirical Formula
252935-94-7C₂₀H₁₇Cl₂N₉O₂

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
5.31167.0001
Récupération des données relatives à la disponibilité...
Disponibilité limitée
Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      Flacon en verre 5 mg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      Demander le prix
      Description
      OverviewA cell-permeable, brain permeant aminopyrimidine compound that acts as a potent, ATP-competitive and reversible inhibitor of both GSK-3α and β (IC50 = 650 and 580 pM, respectively; Ki = 870 pM for human GSK-3β) and significantly affects downstream effects of GSK-3. Displays excellent selectivity over closely related Cdc2 and Erk2 (IC50 = 3.7 µM & > 10 µM, respectively). Does not affect the activity of several other protein kinases studied. Acutely sensitizes glycogen synthase activity in isolated skeletal muscle from insulin-sensitive lean Zucker and insulin-resistant Zucker diabetic fatty (ZDF) rats and can also augment insulin-stimulated glucose uptake in ZDF rats. However, it does not affect the basal glucose uptake rate. Induces a significant reduction in fasting hyperglycemia in diabetic and insulin-resistant db/db mice (~30 mg/kg, s.c.). Reduces Tau phosphorylation (Ser396) in the cortex and hippocampus of postnatal rats. Also shown to activate Wnt/β-catenin signaling and direct the differentiation of human pluripotent stem cells into cardiomyocytes.

      Please note that the molecular weight for this compound is batch-specific due to variable water content.
      Catalogue Number531167
      Brand Family Calbiochem®
      SynonymsN²-(2-(4-(2,4-Dichlorophenyl)-5-(1H-imidazol-1-yl)pyrimidin-2-ylamino)ethyl)-5-nitropyridine-2,6-diamine, N⁶-(2-((4-(2,4-Dichlorophenyl)-5-(1H-imidazol-1-yl)-2-pyrimidinyl)amino}ethyl)-3-nitro-2,6-pyridinediamine, CHIR-98014, CT-98014
      References
      ReferencesGrigoryan, T., et al. 2013. Proc. Natl. Acad. Sci. USA 110, 18174.
      Lian, X., et al. 2012. Proc. Natl. Acad. Sci. USA 109, E1848.
      Selenica, M.L., et al. 2007. Br. J. Pharmacol. 152, 959.
      Ring, D.B., et al. 2003. Diabetes. 52, 588.
      Nikoulina, S.E., et al. 2002. Diabetes. 51, 2190.
      Product Information
      CAS number252935-94-7
      FormYellow powder
      Hill FormulaC₂₀H₁₇Cl₂N₉O₂
      Chemical formulaC₂₀H₁₇Cl₂N₉O₂
      ReversibleY
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetGSK-3 α & β
      Primary Target IC<sub>50</sub>650 and 580 pM for GSK-3&alpha
      Primary Target K<sub>i</sub>870 pM for human GSK-3&beta
      Purity≥95% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      5.31167.0001 04055977283150

      Documentation

      GSK-3 Inhibitor XXIX, CHIR98014 - CAS 252935-94-7 - Calbiochem FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      Références bibliographiques

      Aperçu de la référence bibliographique
      Grigoryan, T., et al. 2013. Proc. Natl. Acad. Sci. USA 110, 18174.
      Lian, X., et al. 2012. Proc. Natl. Acad. Sci. USA 109, E1848.
      Selenica, M.L., et al. 2007. Br. J. Pharmacol. 152, 959.
      Ring, D.B., et al. 2003. Diabetes. 52, 588.
      Nikoulina, S.E., et al. 2002. Diabetes. 51, 2190.

      Informations techniques

      Titre
      Characterization of Estrogen Receptor α Phosphorylation Sites in Breast Cancer Tissue Using the SNAP i.d® 2.0 System
      White Paper: Further considerations of antibody validation and usage.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision27-March-2015 JSW
      SynonymsN²-(2-(4-(2,4-Dichlorophenyl)-5-(1H-imidazol-1-yl)pyrimidin-2-ylamino)ethyl)-5-nitropyridine-2,6-diamine, N⁶-(2-((4-(2,4-Dichlorophenyl)-5-(1H-imidazol-1-yl)-2-pyrimidinyl)amino}ethyl)-3-nitro-2,6-pyridinediamine, CHIR-98014, CT-98014
      DescriptionA cell-permeable, brain permeant aminopyrimidine compound that acts as a potent, ATP-competitive and reversible inhibitor of both GSK-3α and β (IC50 = 650 and 580 pM, respectively; Ki = 870 pM for human GSK-3β) and significantly affects downstream effects of GSK-3. Displays excellent selectivity over closely related Cdc2 and Erk2 (IC50 = 3.7 µM & > 10 µM, respectively). Does not affect the activity of several other protein kinases studied. Acutely sensitizes glycogen synthase activity in isolated skeletal muscle from insulin-sensitive lean Zucker and insulin-resistant Zucker diabetic fatty (ZDF) rats and can also augment insulin-stimulated glucose uptake in ZDF rats. However, it does not affect the basal glucose uptake rate. Induces a significant reduction in fasting hyperglycemia in diabetic and insulin-resistant db/db mice (~30 mg/kg, s.c.). Reduces Tau phosphorylation (Ser396) in the cortex and hippocampus of postnatal rats. Also shown to activate Wnt/β-catenin signaling and direct the differentiation of human pluripotent stem cells into cardiomyocytes.
      FormYellow powder
      Intert gas (Yes/No) Packaged under inert gas
      CAS number252935-94-7
      Chemical formulaC₂₀H₁₇Cl₂N₉O₂
      Purity≥95% by HPLC
      SolubilityDMSO (25 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Standard Handling
      ReferencesGrigoryan, T., et al. 2013. Proc. Natl. Acad. Sci. USA 110, 18174.
      Lian, X., et al. 2012. Proc. Natl. Acad. Sci. USA 109, E1848.
      Selenica, M.L., et al. 2007. Br. J. Pharmacol. 152, 959.
      Ring, D.B., et al. 2003. Diabetes. 52, 588.
      Nikoulina, S.E., et al. 2002. Diabetes. 51, 2190.